HbA1c is a biomarker with a central role in the diagnosis and follow-up of 
patients with diabetes, although not a perfect one. Common comorbidities 
encountered in patients with diabetes mellitus, such as renal insufficiency, 
high output states (iron deficiency anaemia, haemolytic anaemia, 
haemoglobinopathies and pregnancy) and intake of specific drugs could compromise 
the sensitivity and specificity of the biomarker. COVID-19 pandemic poses a 
pressing challenge for the diabetic population, since maintaining optimal blood 
glucose control is key to reduce morbidity and mortality rates. Alternative 
methods for diabetes management, such as fructosamine, glycosylated albumin and 
device-based continuous glucose monitoring, are discussed.